01:33 , Apr 19, 2019 |  BC Innovations  |  Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
18:57 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

ArmaGen reports 52-week Phase II data for MPS I candidate

ArmaGen Inc. (Calabasas, Calif.) reported data from stage 2 of the Phase II portion of a Phase I/II trial in patients ages two and older with severe mucopolysaccharidosis I (MPS I, Hurler syndrome) showing that...
21:09 , Apr 27, 2017 |  BC Week In Review  |  Clinical News

AGT-181: Preliminary Ph I/II AGT-181-101 data

In February, ArmaGen reported preliminary data from 5 children ages ≥2 with Hurler syndrome who had previously received enzyme replacement therapy (ERT) in stage 2 of the open-label, dose-escalation, Brazilian Phase I/II AGT-181-101 trial showing...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Clinical News

AGT-182: Phase I/IIa data

Data from the first cohort of 4 Hunter syndrome patients ages >=18 in the open-label, international Phase I/IIa Breaking Barriers trial showed that once-weekly 1 mg/kg IV AGT-182 for 8 weeks was generally well tolerated....
08:00 , Feb 18, 2016 |  BC Innovations  |  Product R&D

Crossing paths

Selina Koch, Staff Writer  With its first foray into the brain, Catabasis Pharmaceuticals Inc. is using its linker technology to simultaneously target the inflammatory and oxidative stress pathways that drive neurodegeneration, starting with amyotrophic lateral...
08:00 , Jan 18, 2016 |  BioCentury  |  Strategy

Shire's serial story

The most obvious benefits Shire plc expects to gain by acquiring Baxalta Inc. are a slew of new products and the cash to make subsequent acquisitions the company couldn't have made on its own. But...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

HIRMAb-IDUA regulatory update

FDA granted rare pediatric disease designation to AGT-181 from ArmaGen to treat mucopolysaccharidosis I (MPS I, Hurler syndrome). AGT-181 is in Phase I/IIa testing for MPS I. The product is alpha-L-iduronidase (IDUA) fused to an...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

HIRMAb-IDUA: Phase I/IIa started

ArmaGen began an open-label, U.S. Phase I/IIa trial to evaluate 1, 3 and 6-9 mg/kg IV AGT-181 once weekly for 8 weeks in about 9 adult patients. ArmaGen Inc. , Calabasas, Calif.   Product: HIRMAb-IDUA...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Company News

ArmaGen, Shire deal

ArmaGen Inc. (formerly ArmaGen Technologies Inc.) received an undisclosed milestone payment from Shire under a 2014 deal granting Shire rights to AGT-182 . The milestone was triggered by the start of patient dosing in a...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Clinical News

AGT-182: Phase I started

ArmaGen began an open-label, dose-escalation, U.S. Phase I trial to evaluate 1 and 3 mg/kg IV AGT-182 once weekly for 8 weeks in about 12 patients. The trial start triggered an undisclosed milestone payment to...